Chardan Capital Reiterates “Buy” Rating for Applied Molecular Transport (NASDAQ:AMTI)

Applied Molecular Transport (NASDAQ:AMTI – Get Rating)‘s stock had its “buy” rating reiterated by equities researchers at Chardan Capital in a research report issued on Monday, March 6th, Benzinga reports.

Other equities analysts also recently issued research reports about the stock. SVB Leerink reiterated a “market perform” rating on shares of Applied Molecular Transport in a research note on Tuesday, December 27th. Bank of America cut shares of Applied Molecular Transport from a “buy” rating to an “underperform” rating in a report on Thursday, January 5th. Jefferies Financial Group cut shares of Applied Molecular Transport from a “hold” rating to an “underperform” rating in a report on Wednesday, February 8th. Finally, JMP Securities lowered shares of Applied Molecular Transport from a “market outperform” rating to a “market perform” rating in a research report on Friday, December 23rd. Two analysts have rated the stock with a sell rating, two have assigned a hold rating and one has given a buy rating to the company. According to MarketBeat.com, Applied Molecular Transport has an average rating of “Hold” and an average price target of $32.50.

Applied Molecular Transport Stock Up 17.2 %

NASDAQ AMTI traded up $0.06 on Monday, reaching $0.40. The stock had a trading volume of 286,825 shares, compared to its average volume of 236,421. The firm has a market capitalization of $15.61 million, a price-to-earnings ratio of -0.12 and a beta of 2.08. Applied Molecular Transport has a 12-month low of $0.33 and a 12-month high of $8.02. The stock has a fifty day moving average price of $0.57 and a two-hundred day moving average price of $0.89.

Hedge Funds Weigh In On Applied Molecular Transport

Hedge funds have recently made changes to their positions in the business. Vanguard Group Inc. boosted its holdings in shares of Applied Molecular Transport by 41.4% during the third quarter. Vanguard Group Inc. now owns 1,350,774 shares of the company’s stock worth $1,314,000 after purchasing an additional 395,200 shares during the period. UBS Group AG bought a new position in Applied Molecular Transport during the third quarter worth $1,257,000. Renaissance Technologies LLC increased its position in Applied Molecular Transport by 27.6% during the third quarter. Renaissance Technologies LLC now owns 679,300 shares of the company’s stock worth $661,000 after acquiring an additional 147,112 shares during the period. Two Sigma Investments LP boosted its stake in Applied Molecular Transport by 38.7% during the third quarter. Two Sigma Investments LP now owns 356,279 shares of the company’s stock worth $347,000 after buying an additional 99,450 shares in the last quarter. Finally, GSA Capital Partners LLP boosted its stake in Applied Molecular Transport by 148.5% during the fourth quarter. GSA Capital Partners LLP now owns 446,611 shares of the company’s stock worth $188,000 after buying an additional 266,897 shares in the last quarter. Institutional investors and hedge funds own 59.47% of the company’s stock.

Applied Molecular Transport Company Profile

(Get Rating)

Applied Molecular Transport Inc, a clinical-stage biopharmaceutical company, engages in the design and development of a pipeline of oral and respiratory biologic product candidates to treat autoimmune, inflammatory, metabolic, and other diseases. The company's lead product candidate is AMT-101, a gastrointestinal (GI) selective oral fusion of rhIL-10 that is in Phase II clinical trial for the treatment of ulcerative colitis and related inflammatory indications.